ALBANY, New York, September 8, 2014 /PRNewswire/ --
According to a new market report published by Transparency Market Research "Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" six phase III drugs would generate total revenue of USD 3.8 billion by 2020.
Browse the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report at http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
Hospital acquired infections also called as healthcare associated infections or nosocomial infections have raised serious concerns due to multidrug resistance shown by microorganisms. Multidrug resistant organisms are immune to the conventional antibiotics, hence very difficult to treat. Pneumonia accounts for over 22% of all the hospital acquired infections. Since hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator, it is also called as ventilator associated pneumonia. The infection is common in immunocompromised patients, post surgical infections, enteral feeding, and in elderly and infant patients. Various gram positive as well as gram negative bacteria are known to cause hospital acquired pneumonia. Major causative agents include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) is found to be a major causative agent of nosocomial pneumonia in new borne.
Currently there are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage. Phase III candidates include Tedizolid phosphate and Ceftolozane/tazobactam by Cubist Pharmaceuticals, Ceftazidime/avibactam by AstraZeneca PLC, Amikacin inhale by Bayer Healthcare, Plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline. Majority of these drugs are expected to be launched by 2017. Analysis reveals that majority of the candidates in late stage are biological drugs. This indicates a paradigm shift from traditional antibiotic therapy to more sophisticated biological drug therapy. Aridis Pharmaceuticals hold a strong monoclonal antibody pipeline with four candidates for treatment of hospital acquired pneumonia which was acquired from Kenta Biotech in 2013.
Related & Recently Published Reports by Transparency Market Research
- Molecular Cytogenetics Market: http://www.transparencymarketresearch.com/molecular-diagnostics-market.html
- Pharmacy Automation Systems Market: http://www.transparencymarketresearch.com/pharmacy-automation-systems.html
- Peptide Therapeutics Market: http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
Growing drug resistance has been a major concern in hospitals globally. According to a report published by Centers for Disease Control and Prevention (CDC) in 2013 which considers the U.S. population for study, 63% of Acinetobacter is considered multi drug resistant. Methicillin resistant Staphylococcus aureus (MRSA) is one of the most hazardous organisms causing ventilator-associated pneumonia. CDC estimates that over 80,400 MRSA infections occurred in 2011, of which more than 11,000 patients died. Furthermore, World Health Organization (WHO) suggests that prevalence of nosocomial infections is higher in low and middle income countries. This suggests that the conditions are more alarming in these regions. In addition, rate of hospital acquired infections have been declining since recent past according to statistics published by Office National Statistics, U.K.
Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.
Get Sample Copy of Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881
Hospital Acquired Pneumonia Drug Pipeline is as follows:
Global Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates (Phase III)
- Tedizolid phosphate
- Amikacin inhale
Global Hospital Acquired Pneumonia Drug Pipeline, Early Stage Candidates (Phase II, Phase I and Preclinical Trials)
- AR-101 or KBPA101
- GSK 2189242A
- AR 301 or KBSA301
- AR-104 or KBPA104
- AR-201 or KBRV201
- AR-401 or KBAB401
Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Ms. Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Company Blog: http://www.tmrblog.com/
Company Blog: http://www.europlat.org/
Browse All PR: http://www.transparencymarketresearch.com/press-releases.htm
Browse All Articles: http://www.transparencymarketresearch.com/articles.htm
Browse Press Release "six phase III drugs would generate total revenue of USD 3.8 billion by 2020" at @ http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-pneumonia-drugs.htm
SOURCE Transparency Market Research